Protease inhibition and absorption enhancement by functional nanoparticles for effective oral insulin delivery

Fang Yi Su, Kun Ju Lin, Kiran Sonaje, Shiaw Pyng Wey, Tzu Chen Yen, Yi Cheng Ho, Nilendu Panda, Er-Tuan Chuang, Barnali Maiti, Hsing Wen Sung

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

Complexing agents such as diethylene triamine pentaacetic acid (DTPA) are known to disrupt intestinal tight junctions and inhibit intestinal proteases by chelating divalent metal ions. This study attempts to incorporate these benefits of DTPA in functional nanoparticles (NPs) for oral insulin delivery. To maintain the complexing agent concentrated on the intestinal mucosal surface, where the paracellular permeation enhancement and enzyme inhibition are required, DTPA was covalently conjugated on poly(γ-glutamic acid) (γPGA). The functional NPs were prepared by mixing cationic chitosan (CS) with anionic γPGA-DTPA conjugate. The γPGA-DTPA conjugate inhibited the intestinal proteases substantially, and produced a transient and reversible enhancement of paracellular permeability. The prepared NPs were pH-responsive; with an increasing pH, CS/γPGA-DTPA NPs swelled gradually and disintegrated at a pH value above 7.0. Additionally, the biodistribution of insulin orally delivered by CS/γPGA-DTPA NPs in rats was examined by confocal microscopy and scintigraphy. Experimental results indicate that CS/γPGA-DTPA NPs can promote the insulin absorption throughout the entire small intestine; the absorbed insulin was clearly identified in the kidney and bladder. In addition to producing a prolonged reduction in blood glucose levels, the oral intake of the enteric-coated capsule containing CS/γPGA-DTPA NPs showed a maximum insulin concentration at 4h after treatment. The relative oral bioavailability of insulin was approximately 20%. Results of this study demonstrate the potential role for the proposed formulation in delivering therapeutic proteins by oral route.

Original languageEnglish
Pages (from-to)2801-2811
Number of pages11
JournalBiomaterials
Volume33
Issue number9
DOIs
Publication statusPublished - Mar 2012
Externally publishedYes

Fingerprint

Insulin
Prostaglandins A
Nanoparticles
Peptide Hydrolases
Chitosan
Acids
Enzyme inhibition
diethylenetriamine
Confocal microscopy
Tight Junctions
Chelation
Confocal Microscopy
Permeation
Radionuclide Imaging
Biological Availability
Small Intestine
Capsules
Metal ions
Blood Glucose
Rats

Keywords

  • Adherens junction
  • Complexing agent
  • Molecular dynamic simulation
  • Oral protein delivery
  • Proteolytic inhibition

ASJC Scopus subject areas

  • Biomaterials
  • Bioengineering
  • Ceramics and Composites
  • Mechanics of Materials
  • Biophysics

Cite this

Su, F. Y., Lin, K. J., Sonaje, K., Wey, S. P., Yen, T. C., Ho, Y. C., ... Sung, H. W. (2012). Protease inhibition and absorption enhancement by functional nanoparticles for effective oral insulin delivery. Biomaterials, 33(9), 2801-2811. https://doi.org/10.1016/j.biomaterials.2011.12.038

Protease inhibition and absorption enhancement by functional nanoparticles for effective oral insulin delivery. / Su, Fang Yi; Lin, Kun Ju; Sonaje, Kiran; Wey, Shiaw Pyng; Yen, Tzu Chen; Ho, Yi Cheng; Panda, Nilendu; Chuang, Er-Tuan; Maiti, Barnali; Sung, Hsing Wen.

In: Biomaterials, Vol. 33, No. 9, 03.2012, p. 2801-2811.

Research output: Contribution to journalArticle

Su, FY, Lin, KJ, Sonaje, K, Wey, SP, Yen, TC, Ho, YC, Panda, N, Chuang, E-T, Maiti, B & Sung, HW 2012, 'Protease inhibition and absorption enhancement by functional nanoparticles for effective oral insulin delivery', Biomaterials, vol. 33, no. 9, pp. 2801-2811. https://doi.org/10.1016/j.biomaterials.2011.12.038
Su, Fang Yi ; Lin, Kun Ju ; Sonaje, Kiran ; Wey, Shiaw Pyng ; Yen, Tzu Chen ; Ho, Yi Cheng ; Panda, Nilendu ; Chuang, Er-Tuan ; Maiti, Barnali ; Sung, Hsing Wen. / Protease inhibition and absorption enhancement by functional nanoparticles for effective oral insulin delivery. In: Biomaterials. 2012 ; Vol. 33, No. 9. pp. 2801-2811.
@article{9b860e69c0d546fb8263e5778d142e89,
title = "Protease inhibition and absorption enhancement by functional nanoparticles for effective oral insulin delivery",
abstract = "Complexing agents such as diethylene triamine pentaacetic acid (DTPA) are known to disrupt intestinal tight junctions and inhibit intestinal proteases by chelating divalent metal ions. This study attempts to incorporate these benefits of DTPA in functional nanoparticles (NPs) for oral insulin delivery. To maintain the complexing agent concentrated on the intestinal mucosal surface, where the paracellular permeation enhancement and enzyme inhibition are required, DTPA was covalently conjugated on poly(γ-glutamic acid) (γPGA). The functional NPs were prepared by mixing cationic chitosan (CS) with anionic γPGA-DTPA conjugate. The γPGA-DTPA conjugate inhibited the intestinal proteases substantially, and produced a transient and reversible enhancement of paracellular permeability. The prepared NPs were pH-responsive; with an increasing pH, CS/γPGA-DTPA NPs swelled gradually and disintegrated at a pH value above 7.0. Additionally, the biodistribution of insulin orally delivered by CS/γPGA-DTPA NPs in rats was examined by confocal microscopy and scintigraphy. Experimental results indicate that CS/γPGA-DTPA NPs can promote the insulin absorption throughout the entire small intestine; the absorbed insulin was clearly identified in the kidney and bladder. In addition to producing a prolonged reduction in blood glucose levels, the oral intake of the enteric-coated capsule containing CS/γPGA-DTPA NPs showed a maximum insulin concentration at 4h after treatment. The relative oral bioavailability of insulin was approximately 20{\%}. Results of this study demonstrate the potential role for the proposed formulation in delivering therapeutic proteins by oral route.",
keywords = "Adherens junction, Complexing agent, Molecular dynamic simulation, Oral protein delivery, Proteolytic inhibition",
author = "Su, {Fang Yi} and Lin, {Kun Ju} and Kiran Sonaje and Wey, {Shiaw Pyng} and Yen, {Tzu Chen} and Ho, {Yi Cheng} and Nilendu Panda and Er-Tuan Chuang and Barnali Maiti and Sung, {Hsing Wen}",
year = "2012",
month = "3",
doi = "10.1016/j.biomaterials.2011.12.038",
language = "English",
volume = "33",
pages = "2801--2811",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier Science Ltd",
number = "9",

}

TY - JOUR

T1 - Protease inhibition and absorption enhancement by functional nanoparticles for effective oral insulin delivery

AU - Su, Fang Yi

AU - Lin, Kun Ju

AU - Sonaje, Kiran

AU - Wey, Shiaw Pyng

AU - Yen, Tzu Chen

AU - Ho, Yi Cheng

AU - Panda, Nilendu

AU - Chuang, Er-Tuan

AU - Maiti, Barnali

AU - Sung, Hsing Wen

PY - 2012/3

Y1 - 2012/3

N2 - Complexing agents such as diethylene triamine pentaacetic acid (DTPA) are known to disrupt intestinal tight junctions and inhibit intestinal proteases by chelating divalent metal ions. This study attempts to incorporate these benefits of DTPA in functional nanoparticles (NPs) for oral insulin delivery. To maintain the complexing agent concentrated on the intestinal mucosal surface, where the paracellular permeation enhancement and enzyme inhibition are required, DTPA was covalently conjugated on poly(γ-glutamic acid) (γPGA). The functional NPs were prepared by mixing cationic chitosan (CS) with anionic γPGA-DTPA conjugate. The γPGA-DTPA conjugate inhibited the intestinal proteases substantially, and produced a transient and reversible enhancement of paracellular permeability. The prepared NPs were pH-responsive; with an increasing pH, CS/γPGA-DTPA NPs swelled gradually and disintegrated at a pH value above 7.0. Additionally, the biodistribution of insulin orally delivered by CS/γPGA-DTPA NPs in rats was examined by confocal microscopy and scintigraphy. Experimental results indicate that CS/γPGA-DTPA NPs can promote the insulin absorption throughout the entire small intestine; the absorbed insulin was clearly identified in the kidney and bladder. In addition to producing a prolonged reduction in blood glucose levels, the oral intake of the enteric-coated capsule containing CS/γPGA-DTPA NPs showed a maximum insulin concentration at 4h after treatment. The relative oral bioavailability of insulin was approximately 20%. Results of this study demonstrate the potential role for the proposed formulation in delivering therapeutic proteins by oral route.

AB - Complexing agents such as diethylene triamine pentaacetic acid (DTPA) are known to disrupt intestinal tight junctions and inhibit intestinal proteases by chelating divalent metal ions. This study attempts to incorporate these benefits of DTPA in functional nanoparticles (NPs) for oral insulin delivery. To maintain the complexing agent concentrated on the intestinal mucosal surface, where the paracellular permeation enhancement and enzyme inhibition are required, DTPA was covalently conjugated on poly(γ-glutamic acid) (γPGA). The functional NPs were prepared by mixing cationic chitosan (CS) with anionic γPGA-DTPA conjugate. The γPGA-DTPA conjugate inhibited the intestinal proteases substantially, and produced a transient and reversible enhancement of paracellular permeability. The prepared NPs were pH-responsive; with an increasing pH, CS/γPGA-DTPA NPs swelled gradually and disintegrated at a pH value above 7.0. Additionally, the biodistribution of insulin orally delivered by CS/γPGA-DTPA NPs in rats was examined by confocal microscopy and scintigraphy. Experimental results indicate that CS/γPGA-DTPA NPs can promote the insulin absorption throughout the entire small intestine; the absorbed insulin was clearly identified in the kidney and bladder. In addition to producing a prolonged reduction in blood glucose levels, the oral intake of the enteric-coated capsule containing CS/γPGA-DTPA NPs showed a maximum insulin concentration at 4h after treatment. The relative oral bioavailability of insulin was approximately 20%. Results of this study demonstrate the potential role for the proposed formulation in delivering therapeutic proteins by oral route.

KW - Adherens junction

KW - Complexing agent

KW - Molecular dynamic simulation

KW - Oral protein delivery

KW - Proteolytic inhibition

UR - http://www.scopus.com/inward/record.url?scp=84855967689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855967689&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2011.12.038

DO - 10.1016/j.biomaterials.2011.12.038

M3 - Article

VL - 33

SP - 2801

EP - 2811

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 9

ER -